Virologic monitoring of hepatitis B virus therapy in clinical trials and practice: recommendations for a standardized approach.
暂无分享,去创建一个
Jean-Michel Pawlotsky | Geoffrey Dusheiko | Fabien Zoulim | Angelos Hatzakis | D. Richman | J. Pawlotsky | F. Zoulim | A. Hatzakis | S. Locarnini | G. Dusheiko | T. Liang | Douglas D Richman | D. Lau | Stephen Locarnini | Paul L. Martin | Paul Martin | T Jake Liang | Daryl Lau | George Lau | G. Lau
[1] C. Gibbs,et al. Persistence of cccDNA during the natural history of chronic hepatitis B and decline during adefovir dipivoxil therapy. , 2004, Gastroenterology.
[2] K. Lole,et al. Quantitation of hepatitis B virus DNA by real-time PCR using internal amplification control and dual TaqMan MGB probes. , 2006, Journal of virological methods.
[3] M. Wulfsohn,et al. Adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B. , 2003, The New England journal of medicine.
[4] N. Leung,et al. A one-year trial of lamivudine for chronic hepatitis B. Asia Hepatitis Lamivudine Study Group. , 1998, The New England journal of medicine.
[5] R. Michael. B Virus Infection , 1966 .
[6] Oliver N Keene,et al. Lamivudine for patients with chronic hepatitis B and advanced liver disease. , 2004, The New England journal of medicine.
[7] M. Yuen,et al. The Natural History and Treatment of Chronic Hepatitis B: A Critical Evaluation of Standard Treatment Criteria and End Points , 2007, Annals of Internal Medicine.
[8] S. Hadziyannis,et al. Interferon alpha treatment and retreatment of hepatitis B e antigen-negative chronic hepatitis B. , 2001, Gastroenterology.
[9] D. Richman. The impact of drug resistance on the effectiveness of chemotherapy for chronic hepatitis B , 2000, Hepatology.
[10] J. Villeneuve,et al. Selection of a multiple drug-resistant hepatitis B virus strain in a liver-transplanted patient. , 2006, Gastroenterology.
[11] D. Pillay,et al. Analysis of Hepatitis B Virus Quasispecies Changes during Emergence and Reversion of Lamivudine Resistance in Liver Transplantation , 1999, Antiviral therapy.
[12] C. Mazzucco,et al. Two-Year Assessment of Entecavir Resistance in Lamivudine-Refractory Hepatitis B Virus Patients Reveals Different Clinical Outcomes Depending on the Resistance Substitutions Present , 2006, Antimicrobial Agents and Chemotherapy.
[13] M. Hirsch,et al. Pharmacogenetics of long-term responses to antiretroviral regimens containing Efavirenz and/or Nelfinavir: an Adult Aids Clinical Trials Group Study. , 2005, The Journal of infectious diseases.
[14] J. Koskinas,et al. Intrahepatic levels and replicative activity of covalently closed circular hepatitis B virus DNA in chronically infected patients , 2006, Hepatology.
[15] F. Zoulim,et al. Transient selection of a hepatitis B virus polymerase gene mutant associated with a decreased replication capacity and famciclovir resistance , 1999, Hepatology.
[16] A. Kidd,et al. Genetic variability in hepatitis B viruses. , 2002, The Journal of general virology.
[17] F. Rousseau,et al. Serum HBV DNA as a marker of efficacy during therapy for chronic HBV infection: Analysis and review of the literature , 2003, Hepatology.
[18] D. Fong,et al. Clinical significance of intrahepatic hepatitis B virus covalently closed circular DNA in chronic hepatitis B patients who received cytotoxic chemotherapy. , 2005, Blood.
[19] George Kitis,et al. Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B for up to 5 years. , 2006, Gastroenterology.
[20] A. Detsky,et al. Effect of Alpha-Interferon Treatment in Patients with Hepatitis B e Antigen-Positive Chronic Hepatitis B , 1993, Annals of Internal Medicine.
[21] C. Chu,et al. Genotype C hepatitis B virus infection is associated with a higher risk of reactivation of hepatitis B and progression to cirrhosis than genotype B: a longitudinal study of hepatitis B e antigen-positive patients with normal aminotransferase levels at baseline. , 2005, Journal of hepatology.
[22] M. Yuen,et al. Effect of Lamivudine Therapy on the Serum Covalently Closed-Circular (ccc) DNA of Chronic Hepatitis B Infection , 2005, The American Journal of Gastroenterology.
[23] J. Germer,et al. Evaluation of the MagNA Pure LC used with the TRUGENE HBV Genotyping Kit. , 2005, Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology.
[24] Chien-Jen Chen,et al. Predicting cirrhosis risk based on the level of circulating hepatitis B viral load. , 2006, Gastroenterology.
[25] M. Manns,et al. In Vitro Susceptibilities of Wild-Type or Drug-Resistant Hepatitis B Virus to (−)-β-d-2,6-Diaminopurine Dioxolane and 2′-Fluoro-5-Methyl-β-l-Arabinofuranosyluracil , 2001, Antimicrobial Agents and Chemotherapy.
[26] Guan-Tarn Huang,et al. Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level. , 2006, JAMA.
[27] H. Janssen,et al. Treatment with Peg-Interferon α-2b for HBeAg-Positive Chronic Hepatitis B: HBsAg Loss Is Associated with HBV Genotype , 2006, The American Journal of Gastroenterology.
[28] P. Cane,et al. Quantitation of hepatitis B lamivudine resistant mutants by real-time amplification refractory mutation system PCR. , 2004, Journal of hepatology.
[29] A. Heath,et al. An international collaborative study to establish a World Health Organization international standard for hepatitis B virus DNA nucleic acid amplification techniques , 2001, Vox sanguinis.
[30] Ying,et al. Lamivudine, adefovir and tenofovir exhibit long‐lasting anti‐hepatitis B virus activity in cell culture , 2000, Journal of viral hepatitis.
[31] Thomas Berg,et al. Peginterferon Alfa-2a, lamivudine, and the combination for HBeAg-positive chronic hepatitis B. , 2005, The New England journal of medicine.
[32] A. Lok,et al. World‐wide epidemiology of HBeAg‐negative chronic hepatitis B and associated precore and core promoter variants , 2002, Journal of viral hepatitis.
[33] J. Pawlotsky. The concept of hepatitis B virus mutant escape. , 2005, Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology.
[34] G. Boiteau,et al. J. Virol. Methods , 1996, Journal of Virological Methods.
[35] Jean-Michel Pawlotsky,et al. Molecular diagnosis of viral hepatitis. , 2002, Gastroenterology.
[36] J. Villeneuve,et al. Stepwise process for the development of entecavir resistance in a chronic hepatitis B virus infected patient. , 2007, Journal of hepatology.
[37] V. Wong,et al. Intrahepatic hepatitis B virus covalently closed circular DNA can be a predictor of sustained response to therapy. , 2005, Gastroenterology.
[38] E. Schiff,et al. Histological outcome during long-term lamivudine therapy. , 2003, Gastroenterology.
[39] J. Pawlotsky,et al. Expertise of Laboratories in Viral Load Quantification, Genotyping, and Precore Mutant Determination for Hepatitis B Virus in a Multicenter Study , 2006, Journal of Clinical Microbiology.
[40] D. Ganem,et al. Hepatitis B virus infection--natural history and clinical consequences. , 2004, The New England journal of medicine.
[41] B. Robertson,et al. Genotype H: a new Amerindian genotype of hepatitis B virus revealed in Central America. , 2002, The Journal of general virology.
[42] M. Manns,et al. In vitro susceptibilities of wild-type or drug-resistant hepatitis B virus to (-)-beta-D-2,6-diaminopurine dioxolane and 2'-fluoro-5-methyl-beta-L-arabinofuranosyluracil. , 2001, Antimicrobial agents and chemotherapy.
[43] P. Angus,et al. Clinical Emergence of Entecavir-Resistant Hepatitis B Virus Requires Additional Substitutions in Virus Already Resistant to Lamivudine , 2004, Antimicrobial Agents and Chemotherapy.
[44] F. Zoulim. New insight on hepatitis B virus persistence from the study of intrahepatic viral cccDNA. , 2005, Journal of hepatology.
[45] Y. Chao,et al. Peginterferon α‐2a (40 kDa): an advance in the treatment of hepatitis B e antigen‐positive chronic hepatitis B , 2003, Journal of viral hepatitis.
[46] J. Pawlotsky,et al. [55] COMPLEX DYNAMICS OF HEPATITIS B VIRUS RESISTANCE TO ADEFOVIR DIPIVOXIL , 2007 .
[47] E. Schiff,et al. Lamivudine as initial treatment for chronic hepatitis B in the United States. , 1999, The New England journal of medicine.
[48] W. Delaney,et al. Phenylpropenamide Derivatives AT-61 and AT-130 Inhibit Replication of Wild-Type and Lamivudine-Resistant Strains of Hepatitis B Virus In Vitro , 2002, Antimicrobial Agents and Chemotherapy.
[49] T Ichida,et al. Geographic distribution of hepatitis B virus (HBV) genotype in patients with chronic HBV infection in Japan , 2001, Hepatology.
[50] Ching-Lung Lai,et al. Long-term safety of lamivudine treatment in patients with chronic hepatitis B. , 2003, Gastroenterology.
[51] M. Casal,et al. Evaluation of the COBAS TaqMan 48 Real-Time PCR System for Quantitation of Hepatitis B Virus DNA , 2005, Journal of Clinical Microbiology.
[52] E. Keeffe,et al. Management of Antiviral Resistance in Patients with Chronic Hepatitis B , 2004, Antiviral therapy.
[53] J. Pawlotsky. Hepatitis B virus (HBV) DNA assays (methods and practical use) and viral kinetics. , 2003, Journal of hepatology.
[54] T. Ide,et al. A real-time quantitative polymerase chain reaction method for hepatitis B virus in patients with chronic hepatitis B treated with lamivudine , 2003, American Journal of Gastroenterology.
[55] F. Zoulim. Assessment of treatment efficacy in HBV infection and disease. , 2006, Journal of hepatology.
[56] M. Manns,et al. Cross-Resistance Testing of Antihepadnaviral Compounds Using Novel Recombinant Baculoviruses Which Encode Drug-Resistant Strains of Hepatitis B Virus , 2001, Antimicrobial Agents and Chemotherapy.
[57] A. Cross,et al. A comparison of entecavir and lamivudine for HBeAg-positive chronic hepatitis B. , 2006, The New England journal of medicine.
[58] B. McMahon,et al. Hepatitis B virus genotypes in Alaska Native people with hepatocellular carcinoma : Preponderance of genotype F. Commentary , 2007 .
[59] A. Lok,et al. Sensitive Line Probe Assay That Simultaneously Detects Mutations Conveying Resistance to Lamivudine and Adefovir , 2006, Journal of Clinical Microbiology.
[60] N. Leung,et al. Extended lamivudine treatment in patients with chronic hepatitis B enhances hepatitis B e antigen seroconversion rates: Results after 3 years of therapy , 2001, Hepatology.
[61] L. Stuyver,et al. Rapid detection of genotypes and mutations in the pre-core promoter and the pre-core region of hepatitis B virus genome: correlation with viral persistence and disease severity. , 2000, Journal of hepatology.
[62] Chien-Jen Chen,et al. Hepatitis B virus genotype and DNA level and hepatocellular carcinoma: a prospective study in men. , 2005, Journal of the National Cancer Institute.
[63] J. Schellens,et al. Novel deoxycytidine kinase gene polymorphisms: a population screening study in Caucasian healthy volunteers , 2006, European Journal of Clinical Pharmacology.
[64] L. Stuyver,et al. Early detection of viral resistance by determination of hepatitis B virus polymerase mutations in patients treated by lamivudine for chronic hepatitis B , 2000, Hepatology.
[65] R. Colonno,et al. 490 High barrier to resistance results in no emergence of entecavir resistance in nucleoside-naïve subjects during the first two years of therapy , 2006 .
[66] M. Wulfsohn,et al. Adefovir dipivoxil for the treatment of hepatitis B e antigen-negative chronic hepatitis B. , 2003, The New England journal of medicine.
[67] J. Pawlotsky,et al. Dynamics of Hepatitis B Virus Resistance to Lamivudine , 2006, Journal of Virology.
[68] H. Leying,et al. Fully automated quantitation of hepatitis B virus (HBV) DNA in human plasma by the COBAS AmpliPrep/COBAS TaqMan system. , 2006, Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology.
[69] M. Yuen,et al. Comparison of the COBAS TaqMan™ HBV test with the COBAS Amplicor monitor™ test for measurement of hepatitis B virus DNA in serum , 2005, Journal of medical virology.
[70] A. Lok,et al. When to Start and Stop Hepatitis B Treatment: Can One Set of Criteria Apply to All Patients Regardless of Age at Infection? , 2007, Annals of Internal Medicine.
[71] P. Schirmacher,et al. Peginterferon alpha‐2b plus adefovir induce strong cccDNA decline and HBsAg reduction in patients with chronic hepatitis B , 2006, Hepatology.
[72] S. Ahn,et al. Evaluation of Methods for Monitoring Drug Resistance in Chronic Hepatitis B Patients during Lamivudine Therapy Based on Mass Spectrometry and Reverse Hybridization , 2005, Antiviral therapy.
[73] J. Villeneuve,et al. Detection of rtN236T and rtA181V/T Mutations Associated with Resistance to Adefovir Dipivoxil in Samples from Patients with Chronic Hepatitis B Virus Infection by the INNO-LiPA HBV DR Line Probe Assay (Version 2) , 2006, Journal of Clinical Microbiology.
[74] Ding‐Shinn Chen,et al. Hepatitis B Virus Infection , 2007 .
[75] K. Walters,et al. Generation of Stable Cell Lines Expressing Lamivudine-Resistant Hepatitis B Virus for Antiviral-Compound Screening , 2003, Antimicrobial Agents and Chemotherapy.
[76] B. McMahon,et al. Hepatitis B virus genotypes in Alaska Native people with hepatocellular carcinoma: preponderance of genotype F. , 2007, The Journal of infectious diseases.
[77] P. Marcellin,et al. Peginterferon alfa-2a alone, lamivudine alone, and the two in combination in patients with HBeAg-negative chronic hepatitis B. , 2004, The New England journal of medicine.
[78] E. Schiff,et al. A Randomized, Controlled Trial of Interferon Alfa-2b Alone and after Prednisone Withdrawal for the Treatment of Chronic Hepatitis B , 1990 .
[79] F. Zoulim,et al. A new strategy for studying In Vitro the drug susceptibility of clinical isolates of human hepatitis B virus , 2004, Hepatology.
[80] N. Kim,et al. Detection of hepatitis B virus YMDD variants using mass spectrometric analysis of oligonucleotide fragments. , 2004, Journal of hepatology.
[81] G. Gerken,et al. Pegylated interferon alfa-2b alone or in combination with lamivudine for HBeAg-positive chronic hepatitis B: a randomised trial , 2005, The Lancet.
[82] S. Zeuzem,et al. Telbivudine Globe Trial: Maximal Early HBV Suppression is Predictive of Optimal Two-year Efficacy in Nucleoside-treated Hepatitis B Patients , 2006 .
[83] M. Yuen,et al. Quantitation of covalently closed circular hepatitis B virus DNA in chronic hepatitis B patients , 2004, Hepatology.
[84] M. Yuen,et al. Factors associated with hepatitis B virus DNA breakthrough in patients receiving prolonged lamivudine therapy , 2001, Hepatology.
[85] Angeline Bartholomeusz,et al. HBV drug resistance: mechanisms, detection and interpretation. , 2006, Journal of hepatology.
[86] S. Hadziyannis,et al. Interferon α Treatment and Retreatment of Hepatitis B e Antigen-Negative Chronic Hepatitis B , 2001 .
[87] U. Akarca,et al. Comparison of Sequence Analysis and INNO-LiPA HBV DR Line Probe Assay in Patients with Chronic Hepatitis B , 2005, Journal of chemotherapy.
[88] F. Zoulim. Mechanism of viral persistence and resistance to nucleoside and nucleotide analogs in chronic hepatitis B virus infection. , 2004, Antiviral research.
[89] A. Bisceglie,et al. Two-year Results from the Globe Trial in Patients with Hepatitis B: Greater Clinical and Antiviral Efficacy for Telbivudine (LdT) vs Lamivudine , 2006 .
[90] C. Ronsin,et al. Evaluation of the COBAS AmpliPrep-Total Nucleic Acid Isolation-COBAS TaqMan Hepatitis B Virus (HBV) Quantitative Test and Comparison to the VERSANT HBV DNA 3.0 Assay , 2006, Journal of Clinical Microbiology.
[91] Angeline Bartholomeusz,et al. Antiviral drug‐resistant HBV: Standardization of nomenclature and assays and recommendations for management , 2007, Hepatology.
[92] Michael D. Miller,et al. Intracellular Metabolism and In Vitro Activity of Tenofovir against Hepatitis B Virus , 2006, Antimicrobial Agents and Chemotherapy.
[93] Ching-Lung Lai,et al. Prevalence and clinical correlates of YMDD variants during lamivudine therapy for patients with chronic hepatitis B. , 2003, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.